Response to: norepinephrine formulation for equivalent vasopressive score
Critical Care volume 27, Article number: 125 (2023)
We thank Mongardon et al. for their interest in our manuscript on an updated norepinephrine equivalent score in intensive care . They correctly pointed out that two formulations of norepinephrine (2 mg/mL and 1 mg/mL) are available in different countries and hospitals .
Extensive research in drug agency databases and contacts with colleagues in five continents surprisingly showed that norepinephrine (better defined as norepinephrine base) is unavailable in the market. Each country has one or more commercially available products, which are different salt formulations, named tartrate, bitartrate, hemitartrate, hydrochloride, or maleate. On average, norepinephrine salts seem to be half potent as norepinephrine base (although pharmacists would consider it as a matter of dilution, not potency). Even if these issues have existed in the last decades, they have not been addressed properly.
Since expert physicians carefully and judiciously titrate norepinephrine with a blood pressure target, the dose is patient-tailored in most situations. It is also true that initiation of a second- and third-line vasoconstrictor, use of off-label vasoconstrictors, and administration of mechanical circulatory support might be triggered by the administered dose as expressed by µg/kg/min. It is unknown whether the experts writing the guidelines, commentaries, and existing vasoactive equivalent scores were referring to norepinephrine base, which does not exist and has never existed, or norepinephrine salts. From the pharmacological point of view, it would be correct to expect that the drug is prepared by pharmacists and nurses worldwide according to norepinephrine base dose equivalence, and therefore, this is what guidelines and existing vasoactive scores are likely referring to. At the same time, situations are likely very jeopardized globally between different intensive care units and hospitals in the same country using different doses, either norepinephrine base or less potent (more diluted) norepinephrine salts.
Multidisciplinary and international consensus concerning the formulation used to describe norepinephrine dose would help prevent dosing confusion in daily practice and facilitate interpreting clinical trial findings in different settings.
Availability of data and materials
Further information is available from the corresponding authors upon reasonable request.
Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity. Crit Care. 2023;27(1):29.
Mongardon N, de Roux Q, Leone M, Guerci P. Norepinephrine formulation for equivalent vasopressive score. Crit Care. 2023;27(1):62.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr. Yuki Kotani receives support from the Uehara Memorial Foundation. The funding agency had no role in the study design; collection, management, analysis, and interpretation of data; writing of the report, or the decision to submit the report for publication.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kotani, Y., Landoni, G., Belletti, A. et al. Response to: norepinephrine formulation for equivalent vasopressive score. Crit Care 27, 125 (2023). https://doi.org/10.1186/s13054-023-04404-x